rongliflozin (HEC44616) / HEC Pharm - LARVOL DELTA

ADME Study of [14C]- Rongliflozin in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion

Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd. | Trial completion date: Aug 2022 ➔ Feb 2023

Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • AFP

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus